Latest News

New COVID-19 strain has reached the U.S.


 

A strain of COVID-19 first reported in Japan surfaced at a Kentucky nursing home in the spring.

Deadline, citing a Centers for Disease Control and Prevention report, said 26 residents and 20 workers tested positive for COVID-19 at a skilled care nursing home. The facility has 83 residents and 116 employees.

On March 1, 28 specimens that had been subjected to whole genome sequencing were found to have “mutations aligning with the R.1 lineage,” Deadline said.

About 90% of the facility’s residents and 52% of the staff had received two COVID vaccine doses, the CDC said. Because of the high vaccination rate, the finding raises concerns about “reduced protective immunity” in relation to the R.1 variant, the CDC said.

However, the nursing home case appears to show that the vaccine keeps most people from getting extremely sick, the CDC said. The vaccine was 86.5% protective against symptomatic illness among residents and 87.1% protective for employees.

“Compared with unvaccinated persons, vaccinated persons had reduced risk for SARS-CoV-2 infection and symptomatic COVID-19,” the CDC said. The vaccination of nursing home residents and health care workers “is essential to reduce the risk for symptomatic COVID-19, as is continued focus on infection prevention and control practices,” the CDC said.

Since being reported in Kentucky, R.1 has been detected more than 10,000 times in the United States, Forbes reported, basing that number on entries in the GISAID SARS-CoV-2 database.

Overall, more than 42 million cases of COVID have been reported since the start of the pandemic.

Deadline reported that the R.1 strain was first detected in Japan in January among three members of one family. The family members had no history of traveling abroad, Deadline said, citing an National Institutes of Health report.

The CDC has not classified R.1 as a variant of concern yet but noted it has “several mutations of importance” and “demonstrates evidence of increasing virus transmissibility.”

A version of this article first appeared on WebMD.com.

Recommended Reading

FDA panel backs Pfizer's COVID booster for 65 and older, those at high risk
MDedge Hematology and Oncology
COVID vaccine is safe, effective for children aged 5-11, Pfizer says
MDedge Hematology and Oncology
Moderna vaccine more effective than Pfizer and J&J
MDedge Hematology and Oncology
COVID-19 claims more than 675,000 U.S. lives, surpassing the 1918 flu
MDedge Hematology and Oncology
When children and teens with cancer get COVID-19
MDedge Hematology and Oncology
Doctor who claimed masks hurt health loses license
MDedge Hematology and Oncology
Will ‘Dr. Disinformation’ ever face the music?
MDedge Hematology and Oncology
COVID-detecting dogs pilot first airport program
MDedge Hematology and Oncology
FDA OKs Pfizer COVID booster for 65 and over, those at high risk
MDedge Hematology and Oncology
Your bathroom towel rack has a dirty little secret
MDedge Hematology and Oncology